30 June 2025   The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP), Sanofi reports . Riliprubart also holds this designation for CIDP in the EU and US.   By engineering a human-relevant chronic inflammatory demyelinating polyneuropathy-on-chip as a preclinical tool for disease modelling and drug efficacy testing, Hesperos has played an instrumental role in